Martin D C, Tertzakian G, Ruzics E
Department of Surgery, University of California Irvine.
J Urol. 1990 May;143(5):900-1. doi: 10.1016/s0022-5347(17)40129-7.
We compare the results in recipients of cadaveric renal allografts immunosuppressed with cyclosporine and prednisone to those who received immunosuppression with cyclosporine, azathioprine and prednisone. The 2 groups were compared relative to HLA-ABDR matching, plasma reactive antibodies, cold ischemia time, diabetes as a cause of renal failure and recipient age greater than 50 years. The incidences of clinical allograft rejection and grafts lost to rejection were not significantly different in these 2 groups evaluated at 1 year. In the 2-drug immunosuppressed group the actual 3, 6 and 12-month graft function was 87, 86 and 85%, respectively, compared to 79, 78 and 74%, respectively, in the 3-drug immunosuppressed group. A difference in graft survival was due to graft loss secondary to vascular thrombosis and patient death, and not to immunological events. No advantage was demonstrated for the use of 3-drug immunosuppression for kidney allografts over a 2-drug protocol of cyclosporine and prednisone.
我们将接受环孢素和泼尼松免疫抑制的尸体肾移植受者的结果,与接受环孢素、硫唑嘌呤和泼尼松免疫抑制的受者的结果进行比较。比较了两组在HLA - ABDR配型、血浆反应性抗体、冷缺血时间、作为肾衰竭病因的糖尿病以及年龄大于50岁的受者方面的情况。在1年时评估的这两组中,临床移植物排斥反应的发生率和因排斥反应而丢失移植物的发生率没有显著差异。在两药免疫抑制组中,实际3个月、6个月和12个月的移植物功能分别为87%、86%和85%,而在三药免疫抑制组中分别为79%、78%和74%。移植物存活的差异是由于血管血栓形成继发的移植物丢失和患者死亡,而非免疫事件。与环孢素和泼尼松的两药方案相比,三药免疫抑制用于肾移植并无优势。